Chimie physique générale, Biologie cellulaire oncologique Jean-Bernard REGNOUF de VAINS ........ Chimie thérapeutique Bertrand RIHN .................................. Biochimie, Biologie ,
Chimie thérapeutique François BONNEAUX Chimie thérapeutique ,
Biophysique, Informatique Christine PERDICAKIS ........................ Chimie ,
Biological rythm in psychiatry, Biochimie et Biologie moléculaire Colette ZINUTTI ................................ Eur Psychiatry, vol.20, pp.99-154, 2005. ,
12-Month comorbidity patterns and associated factors in Europe : results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project, Acta Psychiatr Scand, vol.109, pp.28-37, 2004. ,
Cost of affective disorders in Europe, European Journal of Neurology, vol.21, issue.s1, pp.34-38, 2005. ,
DOI : 10.1192/bjp.184.5.386
Melatonin and Human Rhythms, Chronobiology International, vol.341, issue.1, pp.21-37, 2006. ,
DOI : 10.1016/S0304-3940(03)00122-8
URL : http://rcin.org.pl/Content/29017
New selective ligands of human cloned melatonin MT1 and MT2 receptors, Naunyn-Schmiedeberg's Archives of Pharmacology, vol.367, issue.6, pp.553-561, 2003. ,
DOI : 10.1007/s00210-003-0751-2
Agomelatine, a New Antidepressant, Induces Regional Changes in Hippocampal Neurogenesis, Biological Psychiatry, vol.59, issue.11, pp.1087-1096, 2006. ,
DOI : 10.1016/j.biopsych.2005.11.025
URL : https://hal.archives-ouvertes.fr/hal-00087540
Regional dissociations within the hippocampus???memory and anxiety, Neuroscience & Biobehavioral Reviews, vol.28, issue.3, pp.273-283, 2004. ,
DOI : 10.1016/j.neubiorev.2004.03.004
Regulation of corticosteroid receptor gene expression in depression and antidepressant action, J Psychiatry Neurosci, vol.24, pp.25-39, 1999. ,
Antidepressant action of agomelatine (S 20098) in a transgenic mouse model, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.29, issue.6, pp.908-916, 2005. ,
DOI : 10.1016/j.pnpbp.2005.04.032
Digging deep - structure-function relationships in the melatonin receptor family, Journal of Pineal Research, vol.62, issue.4, pp.221-251, 2003. ,
DOI : 10.1095/biolreprod62.4.1096
Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model, Behavioural Pharmacology, vol.17, issue.8, pp.703-713, 2006. ,
DOI : 10.1097/FBP.0b013e3280116e5c
Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling, European Journal of Pharmaceutical Sciences, vol.12, issue.2, pp.117-141, 2000. ,
DOI : 10.1016/S0928-0987(00)00146-9
orientation diagnostique et principes du traitement, La revue du praticien, vol.49, issue.6, pp.643-652, 1999. ,
Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors, J Psychiatry Neurosci, vol.29, pp.126-133, 2004. ,
Protocoles et échelles d'évaluation en psychiatrie et en psychologie, 2002. ,
Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis, BMJ, vol.332, issue.7538, pp.385-93, 2006. ,
DOI : 10.1136/bmj.38731.532766.F6
Electroencephalographic sleep correlates of episode and vulnerability to recurrence in depression, Biological Psychiatry, vol.41, issue.4, pp.406-424, 1997. ,
DOI : 10.1016/S0006-3223(96)00041-8
Role of Melatonin in the Regulation of Human Circadian Rhythms and Sleep, Journal of Neuroendocrinology, vol.505, issue.Suppl. 1, pp.432-437, 2003. ,
DOI : 10.1111/j.1469-7793.1997.851ba.x
Melatonin site and mechanism of action: Single or multiple?, Journal of Pineal Research, vol.21, issue.1, pp.32-39, 1997. ,
DOI : 10.1016/0014-5793(88)80411-3
Therapeutic potential of melatonin agonists, Expert Review of Endocrinology & Metabolism, vol.19, issue.2, pp.269-279, 2008. ,
DOI : 10.1097/01.yic.0000137184.64610.c8
The molecular mechanisms of the circadian clock ,
A molecular perspective of human circadian rhythm disorders, Brain Research Reviews, vol.42, issue.3, pp.204-220, 2003. ,
DOI : 10.1016/S0165-0173(03)00171-1
Chronobiology, excessive daytime sleepiness and depression: Is there a link?, Sleep Medicine, vol.10, issue.5, pp.10-16, 2008. ,
DOI : 10.1016/j.sleep.2008.05.010
M??latonine, rythme veille-sommeil et sommeil, M??decine du Sommeil, vol.1, issue.4, pp.11-19, 2005. ,
DOI : 10.1016/S1769-4493(05)70144-8
The basic physiology and pathophysiology of melatonin, Sleep Medicine Reviews, vol.9, issue.1, pp.11-24, 2005. ,
DOI : 10.1016/j.smrv.2004.08.001
Prevalence of Sexual Dysfunction Among Newer Antidepressants, The Journal of Clinical Psychiatry, vol.63, issue.4, pp.357-366, 2002. ,
DOI : 10.4088/JCP.v63n0414
Characterisation of human melatonin mt1 and MT2 receptors by CRE-luciferase reporter assay, European Journal of Pharmacology, vol.390, issue.1-2, pp.15-24, 2000. ,
DOI : 10.1016/S0014-2999(99)00914-0
D??pression r??currente et ??v??nements de vie : de la clinique ?? de nouveaux mod??les explicatifs ? Enqu??te ACTUEL, L'Enc??phale, vol.32, issue.6, pp.983-987, 2006. ,
DOI : 10.1016/S0013-7006(06)76277-7
Serum melatonin and urinary 6-sulfatoxymelatonin in major depression, Psychoneuroendocrinology, vol.29, issue.1, pp.1-12, 2004. ,
DOI : 10.1016/S0306-4530(02)00123-3
Use of slow-release melatonin in treatment-resistant depression, J Psychiatry Neurosci, vol.25, issue.1, pp.48-52, 2000. ,
MT1 Melatonin Receptor mRNA Expressing Cells in the Pars Tuberalis of the European Hamster: Effect of Photoperiod, Journal of Neuroendocrinology, vol.15, issue.8, pp.778-786, 2003. ,
DOI : 10.1016/S0940-9602(11)80177-9
Therapeutic Perspectives for Melatonin Agonists and Antagonists, Journal of Neuroendocrinology, vol.58, issue.4, pp.442-448, 2003. ,
DOI : 10.1136/oem.58.11.747
URL : https://hal.archives-ouvertes.fr/hal-00409043
Alpha2-adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex, Journal of Neurochemistry, vol.148, issue.4, pp.1003-1009, 2004. ,
DOI : 10.1111/j.1471-4159.1993.tb02168.x
Timing and Consolidation of Human Sleep, Wakefulness, and Performance by a Symphony of Oscillators, Journal of Biological Rhythms, vol.277, issue.4, pp.279-290, 2005. ,
DOI : 10.1113/jphysiol.2004.061606
Melatonin receptors: Are there multiple subtypes?, Trends in Pharmacological Sciences, vol.16, issue.2, pp.50-56, 1995. ,
DOI : 10.1016/S0165-6147(00)88978-6
Functional MT1 and MT2 melatonin receptors in mammals, Endocrine, vol.2, pp.101-110, 2005. ,
The IUPHAR compendium of receptor characterization and classification, IUPHAR Media, 2000. ,
Role of Neurotrophic Factors in the Etiology and Treatment of Mood Disorders, NeuroMolecular Medicine, vol.5, issue.1, pp.11-25, 2004. ,
DOI : 10.1385/NMM:5:1:011
Circadian rhythms and the pharmacology of affective illness, Pharmacology & Therapeutics, vol.71, issue.3, pp.253-312, 1996. ,
DOI : 10.1016/S0163-7258(96)00092-7
Molecular Bases for Circadian Clocks, Cell, vol.96, issue.2, pp.271-290, 1999. ,
DOI : 10.1016/S0092-8674(00)80566-8
Adult neurogenesis: implications for psychiatry, Prog Brain Res, vol.138, pp.315-342, 2002. ,
DOI : 10.1016/S0079-6123(02)38085-3
Questions et réponses sur la recommandation de refus de l'autorisation de mise sur le marché pour VALDOXAN/THYMANAX, Réf. Doc. EMEA, vol.16, issue.01, 2006. ,
Reemergence of Sexual Dysfunction in Patients With Major Depressive Disorder, The Journal of Clinical Psychiatry, vol.62, issue.1, pp.24-29, 2001. ,
DOI : 10.4088/JCP.v62n0106
Light Therapy for Seasonal Affective Disorder with Blue Narrow-Band Light-Emitting Diodes (LEDs), Biological Psychiatry, vol.59, issue.6, pp.502-507, 2006. ,
DOI : 10.1016/j.biopsych.2005.07.006
P.2.c.038 Long-term efficacy of agomelatine, a novel antidepressant, in the prevention of relapse in out-patients with major depressive disorder, European Neuropsychopharmacology, vol.17, issue.4, p.361, 2007. ,
DOI : 10.1016/S0924-977X(07)70529-1
URL : https://hal.archives-ouvertes.fr/hal-00820755
Agonistes et antagonistes des r??cepteurs m??latoninergiques : effets pharmacologiques et perspectives th??rapeutiques, Annales Pharmaceutiques Fran??aises, vol.63, issue.6, pp.385-400, 2005. ,
DOI : 10.1016/S0003-4509(05)82308-9
Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder, Eur Psychopharmacol, vol.15, issue.3, pp.419-439, 2005. ,
How the internal clock interacts with mood and depression, European Psychiatry, vol.22, pp.89-95, 2007. ,
DOI : 10.1016/j.eurpsy.2007.01.1175
Genetics of the sleep-wake cycle and its disorders, Metabolism, vol.55, issue.55, pp.7-12, 2006. ,
DOI : 10.1016/j.metabol.2006.07.006
Pharmacological profile of antidepressants: a likely basis for their efficacy and side effects?, European Neuropsychopharmacology, vol.16, pp.625-632, 2006. ,
DOI : 10.1016/S0924-977X(06)70008-6
Pathophysiology and treatment of affective disorders: melatonin and serotonin, Medicographia, vol.27, issue.3, pp.228-235, 2005. ,
Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain, Neuropharmacology, vol.47, issue.4, pp.515-526, 2004. ,
DOI : 10.1016/j.neuropharm.2004.06.003
Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs, European Journal of Pharmacology, vol.231, issue.2, pp.223-229, 1993. ,
DOI : 10.1016/0014-2999(93)90453-O
Treatment of insomnia associated with clinical depression, Sleep Medicine Reviews, vol.8, issue.1, pp.19-30, 2004. ,
DOI : 10.1016/S1087-0792(03)00025-X
Multiple Effects of Melatonin on Rhythmic Clock Gene Expression in the Mammalian Pars Tuberalis, Endocrinology, vol.147, issue.2, pp.959-965, 2006. ,
DOI : 10.1210/en.2005-1100
URL : https://hal.archives-ouvertes.fr/hal-00093434
Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment, International Clinical Psychopharmacology, vol.17, issue.5, pp.217-225, 2002. ,
DOI : 10.1097/00004850-200209000-00002
), Chronobiology International, vol.141, issue.1-2, pp.225-261, 2006. ,
DOI : 10.2337/diab.45.10.1435
The Rhythm and Blues of Gene Expression in the Rodent Pineal Gland, Endocrine, vol.27, issue.2, pp.89-100, 2005. ,
DOI : 10.1385/ENDO:27:2:089
P.2.c.022 Superior antidepressant efficacy of agomelatine versus sertraline: a randomised, double-blind study, European Neuropsychopharmacology, vol.18, pp.336-337, 2008. ,
DOI : 10.1016/S0924-977X(08)70468-1
URL : https://hal.archives-ouvertes.fr/in2p3-00293667
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder, European Neuropsychopharmacology, vol.16, issue.2, pp.93-100, 2006. ,
DOI : 10.1016/j.euroneuro.2005.09.002
P.2.c.013 Antidepressant efficacy of agomelatine 25-50 mg versus venlafaxine 75 -150 mg: two randomized, double blind studies, European Neuropsychopharmacology, vol.16, issue.4, pp.319-320, 2006. ,
DOI : 10.1016/S0924-977X(06)70347-9
URL : https://hal.archives-ouvertes.fr/in2p3-00361601
Agomelatine and its therapeutic potential in the depressed patient, Neuropsychiatric Disease and Treatment, vol.4, issue.3, pp.423-428, 2007. ,
SB 242084, a Selective and Brain Penetrant 5-HT 2C Receptor Antagonist, Neuropharmacology, vol.36, issue.4-5, pp.609-620, 1997. ,
DOI : 10.1016/S0028-3908(97)00038-5
The World Health Organization Composite International Diagnostic Interview short-form (CIDI-SF), International Journal of Methods in Psychiatric Research, vol.28, issue.4, pp.171-185, 1998. ,
DOI : 10.1001/archpsyc.1994.03950010008002
Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication, Archives of General Psychiatry, vol.62, issue.6, pp.593-602, 2005. ,
DOI : 10.1001/archpsyc.62.6.593
Frequency of Positive Studies Among Fixed and Flexible Dose Antidepressant Clinical Trials: An Analysis of the Food and Drug Administraton Summary Basis of Approval Reports, Neuropsychopharmacology, vol.52, issue.3, pp.552-557, 2003. ,
DOI : 10.1097/00004850-199403001-00006
Pineal N-acetyltransferase and hydroxyindole-O-methyl-transferase: control by the retinohypothalamic tract and the suprachiasmatic nucleus, Brain Research, vol.174, issue.2, pp.245-62, 1979. ,
DOI : 10.1016/0006-8993(79)90848-5
Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat, Biological Psychiatry, vol.56, issue.8, pp.570-580, 2004. ,
DOI : 10.1016/j.biopsych.2004.07.008
Depression and associated sleep disturbances: patient benefits with agomelatine, European Neuropsychopharmacology, vol.16, issue.5, pp.639-643, 2006. ,
DOI : 10.1016/S0924-977X(06)70010-4
Sleep and treatment prediction in endogenous depression, Am J Psychiatry, vol.138, pp.429-434, 1981. ,
Limitations of current medical treatments for depression: Disturbed circadian rhythms as a possible therapeutic target, European Neuropsychopharmacology, vol.17, issue.12, pp.743-755, 2007. ,
DOI : 10.1016/j.euroneuro.2007.05.004
Sleep disturbances and depression: a challenge for antidepressants, International Clinical Psychopharmacology, vol.21, issue.Supplement 1, pp.25-29, 2006. ,
DOI : 10.1097/01.yic.0000195658.91524.61
Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults., Journal of Affective Disorders, vol.117, pp.26-43, 2009. ,
DOI : 10.1016/j.jad.2009.06.041
Évaluation pharmacoéconomique des épisodes dépressifs majeurs et des récidives, Neuropsy News, vol.5, pp.221-229, 2003. ,
Improvement in Subjective Sleep in Major Depressive Disorder With a Novel Antidepressant, Agomelatine, The Journal of Clinical Psychiatry, vol.68, issue.11, pp.1723-1732, 2007. ,
DOI : 10.4088/JCP.v68n1112
Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men, Clinical Endocrinology, vol.43, issue.3, pp.298-304, 2005. ,
DOI : 10.1016/0165-1781(95)02701-W
Troubles de l???humeur et rythmes biologiques, Annales Pharmaceutiques Fran??aises, vol.66, issue.3, pp.169-174, 2008. ,
DOI : 10.1016/j.pharma.2008.04.005
Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment, Psychosom Med, vol.66, pp.305-315, 2004. ,
Melatonin shifts human circadian rhythms according to a phase-response curve, Chronobiol Int, vol.60, pp.105-117, 1994. ,
The circadian basis of winter depression, Proceedings of the National Academy of Sciences, vol.287, issue.14, pp.7414-7419, 2006. ,
DOI : 10.1001/jama.287.14.1840
Localization of Aa-nat mRNA in the rat retina by fluorescence in situ hybridization and laser capture microdissection, Cell and Tissue Research, vol.315, issue.2, pp.197-201, 2004. ,
DOI : 10.1007/s00441-003-0822-1
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study, Int Clin Psychopharmacol, vol.17, pp.239-247, 2002. ,
Non-REM sleep instability in patients with major depressive disorder: Subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine), Sleep Medicine, vol.9, issue.1, pp.33-41, 2007. ,
DOI : 10.1016/j.sleep.2007.01.011
Human pineal physiology and functional significance of melatonin, Frontiers in Neuroendocrinology, vol.25, issue.3-4, pp.177-195, 2004. ,
DOI : 10.1016/j.yfrne.2004.08.001
Neurobiology of depression: an integrated view of key findings, International Journal of Clinical Practice, vol.35, issue.Suppl. 3, pp.61-2030, 2007. ,
DOI : 10.1176/jnp.9.3.315
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression, Biological Psychiatry, vol.53, issue.8, pp.707-742, 2003. ,
DOI : 10.1016/S0006-3223(03)00117-3
Tolerability and adherence issues in antidepressant therapy, Clinical Therapeutics, vol.25, issue.8, pp.2289-2304, 2003. ,
DOI : 10.1016/S0149-2918(03)80220-5
Melatonin affects the immobility time of rats in the forced swim test: The role of serotonin neurotransmission, European Neuropsychopharmacology, vol.16, issue.7, pp.538-545, 2006. ,
DOI : 10.1016/j.euroneuro.2006.01.005
The role of monoamines in the actions of established and ???novel??? antidepressant agents: a critical review, European Journal of Pharmacology, vol.500, issue.1-3, pp.371-384, 2004. ,
DOI : 10.1016/j.ejphar.2004.07.038
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application, Pharmacology & Therapeutics, vol.110, issue.2, pp.135-370, 2006. ,
DOI : 10.1016/j.pharmthera.2005.11.006
Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents, Journal of Psychopharmacology, vol.24, issue.2, pp.114-138, 2000. ,
DOI : 10.1016/0169-328X(91)90064-5
Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade, Psychopharmacology, vol.35, issue.4, pp.448-458, 2005. ,
DOI : 10.1007/s00213-004-1962-z
The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways, Journal of Pharmacology and Experimental Therapeutics, vol.306, issue.3, pp.954-964, 2003. ,
DOI : 10.1124/jpet.103.051797
The adverse effects of antidepressants, Current Opinion in Psychiatry, vol.10, issue.2, pp.88-94, 1997. ,
DOI : 10.1097/00001504-199703000-00006
The anatomy and innervation of the mammalian pineal gland, Cell and Tissue Research, vol.309, issue.1, pp.139-50, 2002. ,
DOI : 10.1007/s00441-002-0580-5
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients, J Clin Psychiatry, vol.62, issue.3, pp.10-21, 2001. ,
The circadian basis of mood disorders: Recent developments and treatment implications, European Neuropsychopharmacology, vol.18, issue.10, pp.701-711, 2008. ,
DOI : 10.1016/j.euroneuro.2008.06.007
Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist, European Neuropsychopharmacology, vol.16, pp.633-638, 2006. ,
DOI : 10.1016/S0924-977X(06)70009-8
Is severe depression a separate indication?1Chair: SA Montgomery, Y. Lecrubier.Participants: E. Abadie, M. Ackenheil, J. Angst, P. Bech, P. Bouka, M. Briley, S. Eisen, J.-D. Guelfi, S. Kasper, J. Keogeorgos, B. Picon, R.M. Pinder, A. Puech, A. Sitzen, C.R. Soldatos, J.M. Van Ree, B.J. Van Zwieten-Boot.Rapporteur: D.B. Montgomery.1, European Neuropsychopharmacology, vol.9, issue.3, pp.259-264, 1999. ,
DOI : 10.1016/S0924-977X(98)00048-0
Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction, Journal of Affective Disorders, vol.69, issue.1-3, pp.119-159, 2002. ,
DOI : 10.1016/S0165-0327(01)00313-5
Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study, International Clinical Psychopharmacology, vol.19, issue.5, pp.271-280, 2004. ,
DOI : 10.1097/01.yic.0000137184.64610.c8
Melatonin receptors: Localization, molecular pharmacology and physiological significance, Neurochemistry International, vol.24, issue.2, pp.101-146, 1994. ,
DOI : 10.1016/0197-0186(94)90100-7
Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders, The International Journal of Neuropsychopharmacology, vol.7, issue.2 ,
DOI : 10.1017/S1461145704004080
as the Quinone Reductase 2, Journal of Biological Chemistry, vol.261, issue.40, pp.31311-31317, 2000. ,
DOI : 10.1074/jbc.275.12.8794
Continuity of Antidepressant Treatment for Adults With Depression in the United States, American Journal of Psychiatry, vol.163, issue.1, pp.101-108, 2006. ,
DOI : 10.1176/appi.ajp.163.1.101
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder, Int J Neuropsychopharmacol, vol.10, issue.5, pp.661-673, 2007. ,
Melatonin in Psychiatric Disorders: A Review on the Melatonin Involvement in Psychiatry, Frontiers in Neuroendocrinology, vol.22, issue.1, pp.18-32, 2001. ,
DOI : 10.1006/frne.2000.0202
Melatonin and sleep in aging population, Experimental Gerontology, vol.40, issue.12, pp.911-925, 2005. ,
DOI : 10.1016/j.exger.2005.08.009
A Meta-Analysis of Early Sustained Response Rates Between Antidepressants and Placebo for the Treatment of Major Depressive Disorder, Journal of Clinical Psychopharmacology, vol.26, issue.1, pp.56-60, 2006. ,
DOI : 10.1097/01.jcp.0000195042.62724.76
Effect of Agomelatine in the Chronic Mild Stress Model of Depression in the Rat, Neuropsychopharmacology, vol.17, issue.Suppl, pp.694-703, 2003. ,
DOI : 10.3928/0048-5713-19871001-11
Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder, Journal of Affective Disorders, vol.89, issue.1-3, pp.207-212, 2005. ,
DOI : 10.1016/j.jad.2005.09.003
Melatonin: From Seasonal to Circadian Signal, Journal of Neuroendocrinology, vol.876, issue.4, pp.422-426, 2003. ,
DOI : 10.1016/S0006-8993(00)02590-7
Designing a new generation of antidepressant drugs, Acta Psychiatrica Scandinavica, vol.277, issue.s391, pp.7-13, 1997. ,
DOI : 10.1097/00004850-199512004-00006
Effect of agomelatine on the sleep EEG in patients with major depressive disorders, Eur Neuropsychopharmacol, vol.15, issue.3, pp.435-442, 2005. ,
Entrainment of Rat Circadian Rhythms by the Melatonin Agonist S-20098 Requires Intact Suprachiasmatic Nuclei But Not the Pineal, Journal of Biological Rhythms, vol.9, issue.1, pp.39-51, 1998. ,
DOI : 10.1016/0006-8993(93)90682-D
Pineal Melatonin: Cell Biology of Its Synthesis and of Its Physiological Interactions*, Endocrine Reviews, vol.12, issue.2, pp.151-180, 1991. ,
DOI : 10.1210/edrv-12-2-151
The pineal gland and melatonin in relation to aging: A summary of the theories and of the data, Experimental Gerontology, vol.30, issue.3-4, pp.199-212, 1995. ,
DOI : 10.1016/0531-5565(94)00045-5
Oxidative damage in the central nervous system: protection by melatonin, Progress in Neurobiology, vol.56, issue.3, pp.359-384, 1998. ,
DOI : 10.1016/S0301-0082(98)00052-5
Melatonin receptors step into the light: cloning and classification of subtypes, Trends in Pharmacological Sciences, vol.17, issue.3, pp.100-102, 1996. ,
DOI : 10.1016/0165-6147(96)10005-5
Clinical Applications of MAO-Inhibitors, Current Medicinal Chemistry, vol.11, issue.15, pp.2033-2043, 2004. ,
DOI : 10.2174/0929867043364775
Seasonal Affective Disorder, Archives of General Psychiatry, vol.41, issue.1, pp.72-80, 1984. ,
DOI : 10.1001/archpsyc.1984.01790120076010
Efficacy and tolerance profile of agomelatine and practical use in depressed patients, International Clinical Psychopharmacology, vol.21, issue.Supplement 1, pp.31-35, 2006. ,
DOI : 10.1097/01.yic.0000195659.99148.09
Effects of sleep deprivation on Color-Word, Emotional, and Specific Stroop interference and on self-reported anxiety, Brain and Cognition, vol.60, issue.1, pp.76-87, 2006. ,
DOI : 10.1016/j.bandc.2005.10.001
Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system, European Psychiatry, vol.23, issue.6, pp.396-402, 2008. ,
DOI : 10.1016/j.eurpsy.2008.04.002
Requirement of Hippocampal Neurogenesis for the Behavioral Effects of Antidepressants, Science, vol.301, issue.5634, pp.805-809, 2003. ,
DOI : 10.1126/science.1083328
Pharmacological principles of antidepressant efficacy, Human Psychopharmacology: Clinical and Experimental, vol.59, issue.S1, pp.17-22, 2002. ,
DOI : 10.4088/JCP.v59n0606
Cellular oscillators: rhythmic gene expression and metabolism, Current Opinion in Cell Biology, vol.17, issue.2, pp.223-229, 2005. ,
DOI : 10.1016/j.ceb.2005.01.007
Daily rhythm and regulation of clock gene expression in the rat pineal gland, Molecular Brain Research, vol.120, issue.2, pp.164-172, 2004. ,
DOI : 10.1016/j.molbrainres.2003.10.019
Severe Depression, CNS Drugs, vol.79, issue.3, pp.765-776, 2001. ,
DOI : 10.2165/00023210-200115100-00003
Pathophysiology of depression: Role of sleep and the melatonergic system, Psychiatry Research, vol.165, issue.3, pp.201-214, 2009. ,
DOI : 10.1016/j.psychres.2007.11.020
Early Improvement Under Mirtazapine and Paroxetine Predicts Later Stable Response and Remission With High Sensitivity in Patients With Major Depression, The Journal of Clinical Psychiatry, vol.64, issue.4, pp.413-420, 2003. ,
DOI : 10.4088/JCP.v64n0410
Strategies for managing antidepressant-induced sexual dysfunction: Systematic review of randomised controlled trials, Journal of Affective Disorders, vol.88, issue.3, pp.241-254, 2005. ,
DOI : 10.1016/j.jad.2005.07.006
Dysfonctionnements de l???horloge biologique et leurs traitements, Annales Pharmaceutiques Fran??aises, vol.66, issue.3, pp.146-157, 2008. ,
DOI : 10.1016/j.pharma.2008.05.001
Maximizing the Adequacy of Medication Treatment in Controlled Trials and Clinical Practice: STAR*D Measurement-Based Care, Neuropsychopharmacology, vol.58, issue.12, pp.2479-2489, 2007. ,
DOI : 10.1136/jamia.1995.96073834
Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice, American Journal of Psychiatry, vol.163, issue.1, pp.28-40, 2006. ,
DOI : 10.1176/appi.ajp.163.1.28
Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists, Sleep Medicine, vol.5, issue.6, pp.523-532, 2004. ,
DOI : 10.1016/j.sleep.2004.07.009
Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine, Journal of Neurochemistry, vol.412, issue.4, pp.917-927, 2004. ,
DOI : 10.1007/s00213-002-1381-y
Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol.263, issue.5, pp.1582-1591, 2001. ,
DOI : 10.1016/0306-4522(95)00408-4
The onset of effect for escitalopram and its relevance for the clinical management of depression, Current Medical Research and Opinion, vol.22, issue.11, pp.2101-2110, 2006. ,
DOI : 10.1185/030079906X148319
Clinical aspects of the melatonin action: impact of development, aging, and puberty, involvement of melatonin in psychiatric disease and importance of neuroimmunoendocrine interactions, Experientia, vol.123, issue.2, pp.671-81, 1993. ,
DOI : 10.1001/archpsyc.1986.01800090060008
Photoperiodism in Humans and Other Primates: Evidence and Implications, Journal of Biological Rhythms, vol.85, issue.1, pp.348-64, 2001. ,
DOI : 10.1111/j.1469-7793.2000.00695.x
Cross-National Epidemiology of Major Depression and Bipolar Disorder, JAMA: The Journal of the American Medical Association, vol.276, issue.4, pp.293-299, 1996. ,
DOI : 10.1001/jama.1996.03540040037030
Preclinical evaluation of the reinforcing and discriminative stimulus effects of agomelatine (S-20098), a melatonin agonist, Psychopharmacology, vol.140, issue.4, pp.503-509, 1998. ,
DOI : 10.1007/s002130050795
Dopaminergic mechanism of antidepressant action in depressed patients, Journal of Affective Disorders, vol.86, issue.1, pp.37-45, 2005. ,
DOI : 10.1016/j.jad.2004.12.010
Chronobiology and mood disorders, Dialogues in Clin Neurosci, vol.5, pp.315-325, 2003. ,
Size and burden of mental disorders in Europe???a critical review and appraisal of 27 studies, European Neuropsychopharmacology, vol.15, issue.4, pp.357-376, 2005. ,
DOI : 10.1016/j.euroneuro.2005.04.012
SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety, Neuropharmacology, vol.41, issue.2, pp.186-199, 2001. ,
DOI : 10.1016/S0028-3908(01)00054-5
Daily variation in the concentration of melatonin and 5-methoxytryptophol in the goose pineal gland, retina, and plasma, General and Comparative Endocrinology, vol.134, issue.3, pp.296-302, 2003. ,
DOI : 10.1016/S0016-6480(03)00269-7
Critères de l'épisode dépressif majeur selon le DSM-IV A Au moins 5 des symptômes suivants doivent avoir été présents pendant une même période d'une durée de 2 semaines et avoir représenté un changement par rapport au fonctionnement antérieur ; au moins 1 des symptômes est soit ,
au moins 2 des 3 symptômes suivants : (1) Humeur dépressive à un degré nettement anormal pour le sujet, présente pratiquement toute la journée et presque tous les jours, dans une large mesure non influencée par les circonstances ,